Vertex Pharmaceuticals Inc
VRTXToday
+2.51%
5 Days
+3.00%
1 Month
-6.31%
6 Months
+3.82%
Year to Date
+9.44%
1 Year
+28.66%
Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.09% on Jul 8: Key Drivers Unveiled
• Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for ten billion dollars cash. • The acquisition includes a premium exceeding one hundred percent of Crinetics' share price. • Executives sold company shares under pre-arranged trading plans during record-high valuations.
Vertex Pharmaceuticals Inc Stock (VRTX) Closed Up by 3.45% on Jun 22: What Signal Does It Send?
• Rockefeller Capital Management significantly increased its equity stake in Vertex Pharmaceuticals. • Analysts upgraded the stock citing revenue diversification from new drug franchises. • Positive clinical data for the non-opioid pain drug suzetrigine strengthened investor confidence.
Vertex Pharmaceuticals Inc Stock (VRTX) Closed Down by 3.03% on Jun 2: Facts Behind the Movement
• Insider and institutional selling pressured Vertex Pharmaceuticals stock. • FDA accepted BLA for povetacicept, targeting November 30, 2026. • Analysts largely maintain buy ratings despite recent stock decline.
Vertex Pharmaceuticals Inc Stock (VRTX) Moved Up by 8.03% on Mar 10: What Signal Does It Send?
• Povetacicept trial met primary endpoint for kidney disease. • Vertex plans BLA submission by March for accelerated review. • Analysts positive on povetacicept's market potential and stock.
Novo Nordisk A/S Stock (NVO) Moved Down by 3.13% on Mar 10: Facts Behind the Movement
• FDA issued warning letter for adverse drug reporting violations. • Analysts downgraded Novo Nordisk due to pipeline and competition concerns. • Company's 2026 guidance projects sales and profit decline.
Vertex Pharmaceuticals Inc Stock Moved Up by 6.51% on Feb 13: What Signal Does It Send?
• Vertex Pharmaceuticals beat revenue estimates, exceeding analyst expectations. • Analysts issued positive ratings, with Oppenheimer upgrading to "Outperform." • Vertex projects 8-9% revenue growth for 2026, with over $500 million from non-CF products.
Vertex Pharmaceuticals Inc's Score
Media Coverage
Analyst Rating
Vertex Pharmaceuticals Inc Technical Analysis
Technical Indicators
Summary
Moving Average
Financial Indicators
Earnings
Vertex Pharmaceuticals Inc Profile
Ownership
| Shareholders | Proportion |
|---|---|
| Capital World Investors | 10.05% |
| Capital Research Global Investors | 6.82% |
| Vanguard Capital Management, LLC | 6.51% |
| BlackRock Institutional Trust Company, N.A. | 6.00% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 60.15% |
| Investment Advisor/Hedge Fund | 28.02% |
| Pension Fund | 2.27% |
| Research Firm | 2.19% |
Related Instruments
Popular Instruments
